Atezolizumab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Atezolizumab |
| DrugBank ID | DB11595 |
| Brand Names (EU) | Tecentriq |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.98% |
Approved Indication (EMA)
Urothelial carcinoma Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC): after prior platinum containing chemotherapy, or who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1). Early-stage non-small cell lung cancer (NSCLC) Tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and platinum-based chemotherapy for ad
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | prostatic urethra urothelial carcinoma | 99.98% | DL |
| 2 | kidney pelvis sarcomatoid transitional cell carcinoma | 99.98% | DL |
| 3 | infiltrating bladder urothelial carcinoma sarcomatoid variant | 99.98% | DL |
| 4 | renal pelvis papillary urothelial carcinoma | 99.98% | DL |
| 5 | transitional cell carcinoma | 99.97% | DL |
| 6 | uterine ligament adenocarcinoma | 99.93% | DL |
| 7 | endocervical carcinoma | 99.92% | DL |
| 8 | adenoid cystic carcinoma of the cervix uteri | 99.92% | DL |
| 9 | uterine ligament serous adenocarcinoma | 99.92% | DL |
| 10 | signet ring cell variant cervical mucinous adenocarcinoma | 99.91% | DL |
| 11 | intestinal variant cervical mucinous adenocarcinoma | 99.91% | DL |
| 12 | uterine ligament mucinous adenocarcinoma | 99.91% | DL |
| 13 | uterine ligament endometrioid adenocarcinoma | 99.91% | DL |
| 14 | cervical adenosquamous carcinoma, glassy cell variant | 99.91% | DL |
| 15 | endocervical type cervical mucinous adenocarcinoma | 99.91% | DL |
| 16 | cervical mucinous adenocarcinoma, minimal deviation variant | 99.91% | DL |
| 17 | uterine ligament clear cell adenocarcinoma | 99.91% | DL |
| 18 | nasopharyngeal teratoma | 99.86% | DL |
| 19 | odontogenic cyst | 99.86% | DL |
| 20 | epiglottis neoplasm | 99.86% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.